Table of Contents
STATISTICAL ANALYSIS PLAN [ADDRESS_1100634] 14
5. RANDOMIZATION AND BLINDING 14
6. SAMPLE SIZE 15
7. STUDY POPULATIONS 16
Per-Protocol (PP) Population 16
Pharmacodynamic (PD) Population 16
Safety Populations 16
8. STATISTICAL ANALYSIS METHODS 17
8.1 Baseline Characteristics 17
8.1.1 Patient Disposition 17
8.1.2 Demographic and Other Baseline Characteristics 17
8.1.3 Medical History 18
8.1.4 Concomitant Medications 18
8.2 Pharmacodynamic Equivalence Analyses 18
8.2.1 Primary Pharmacodynamic Endpoint 18
8.2.2 Population 19
8.2.3 PC20 Log Transformation 19
8.2.4 NONMEM¬Æ Dataset Preparation [ADDRESS_1100635] 28
8.3.6 Concentration of Methacholine Required to Reduce FEV1 by 20% (PC20)
28
8.3.7 Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second (FEV1) 28
clr_17_08-statistical-methods
TOC 1
8.3.8 Protocol Deviations 28
8.4 Multiple Comparisons 28
8.5 Methods for Handling Missing Data 28
8.6 Interim Analyses 28
9. TABLE, LISTING AND FIGURE SHELLS 28
T16.1.9.1 Summary of Patient Disposition 30
T16.1.9.2 Summary of Protocol Deviations 31
T16.1.9.3 Summary of Patient‚Äôs Treatments Included in the Pharmacodynamic Analysis
32
T16.1.9.4 Summary of Demographic Data and Baseline Characteristics 33
T16.1.9.5 Summary of Demographic Data and Baseline Characteristics 35
T16.1.9.6 Summary of Demographic Data and Baseline Characteristics 35
T16.1.9.7 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV1 by 20% (PC20) 36
T16.1.9.8 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV1 by 20% (PC20) 36
T16.1.9.9 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV1 by 20% (PC20) 36
T16.1.9.10 Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 
second (FEV1) 37
T16.1.9.11 Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 
second (FEV1) 38
T16.1.9.12 Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 
second (FEV1) 38
T16.1.9.13 Overall Summary of Adverse Events 39
T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_1196]
40
T16.[IP_ADDRESS] Summary of Frequency of Serious Adverse Events by [CONTACT_1196]
41
T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_456827] 42
T16.[IP_ADDRESS] Summary of Frequency of Serious Adverse Events by [CONTACT_470642] 43
T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_86945] 44
T16.[IP_ADDRESS] Summary of Frequency of Serious Adverse Events by [CONTACT_86945] [ADDRESS_1100636] 58
L16.2.7.1 Listing of Adverse Events (Safety Population Randomization Period) 59
L16.2.7.2 Listing of Adverse Events (Safety Population Screening Period) [ADDRESS_1100637] Results 61
L16.2.7.4 Listing of Abnormal Physical Examinations 62
L16.2.8.1 Listing of Vital Signs 63
L16.2.8.2 Listing of 12-Lead ECG 64
NTF- Tables and Listings Numberings Change 66
clr_17_08-statistical-methods
TOC 3
 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 1 of 64            
STATISTICAL ANALYSIS PLAN                     
 
 
A Randomized, Single-Dose, Double-Blind, Double- Dummy, Four -Period, Four -Sequence, 
Four-Treatment, Placebo and Active Controlled, Comparative, Multiple-Center, Crossover-
Design, Bronchoprovocation  Study to Evaluate the Pharmacodynamic Equivalence of Albuterol 
Sulfate Inhalation Aerosol, eq 90 mcg base ( Sun Pharmaceuticals Industries Limited ) to 
PROAIR¬Æ HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva Respi[INVESTIGATOR_696], LLC) 
in Subjects Wi th Stable, Mild Asthma  
 
 
Protocol Number: CLR_17_08 
 
 
Sponsor:  
Sun Pharmaceuticals Industries Limited  
Formulation Development Department  
Tandalja, Baroda  
Gujarat, 390020, India 
 
 
 
 
 
 
 
 
 
December 21, 2018 
Final  Version 1.0 
  
clr_17_08-statistical-methods
Page 1

clr_17_08-statistical-methods
Page 2

clr_17_08-statistical-methods
Page 3

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 3 of 64 Revision History  
VERSION DATE DESCRIPTION OF REVISIONS  REVISED 
BY 
[CONTACT_117306] 1.0  September 24, 201 8 New Document   
Final 1.0 December 21, 2018 Incorporate client‚Äôs comments and f inalize 
SAP  
    
  
clr_17_08-statistical-methods
Page 4

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100638] of Abbreviations and Terms 
Abbreviation  Term 
AE Adverse Event  
ADaM  Analysis Data Model  
ANDA  Abbreviated New Drug Application  
ATS  American Thoracic Society  
C Celsius  
CDISC  Clinical Data Standards Interchange Consortium  
CRO  Clinical Research Organization  
ECG  Electrocardiogram  
eCRF  electronic Case Report Form  
eCTD  Electronic Common Technical Document  
¬∞F Fahrenheit  
F Relative bioavailability  
FDA  Food and Drug Administration  
FEV 1 Forced Expi[INVESTIGATOR_117067] (flow rate) in [ADDRESS_1100639]  
kg Kilograms  
mcg Microgram  
MedDRA  Medical Dictionary for Regulatory Activities  
mITT  modified Intent -to-Treat  
mL Milliliter  
NAEPP  National Asthma Education and Prevention Program  
OGD  Office of Generic Drugs  
PC 20 Concentration (mg/mL) of methacholine required to reduce FEV 1 by 20%  
PD Pharmacodynamic  
PP Per-Protocol  
RR Respi[INVESTIGATOR_798090]_17_08-statistical-methods
Page 5

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100640]  .................................................................13  
5. RANDOMIZATION AND BLINDING ....................................................................................13  
6. SAMPLE SIZE  ..........................................................................................................................14  
7. STUDY POPULATIONS  ..........................................................................................................15  
8. STATISTICAL ANALYSIS METHODS  .................................................................................16  
8.1 Baseline Characteristics  ......................................................................................................16  
8.1.1 Patient Disposition  ......................................................................................................16  
8.1.2 Demographic and Other Baseline Characteristics  .......................................................16  
8.1.3 Medical History  ...........................................................................................................17  
8.1.4 Concomitant Medications  ...........................................................................................17  
8.2 Pharmacodynamic Equivalence Analyses ...........................................................................17  
8.2.1 Primary Pharmacodynamic Endpoint  ..........................................................................17  
8.2.2 Population  ....................................................................................................................18  
8.2.3 PC 20 Log Transformation ............................................................................................18  
8.2.4 NONMEM¬Æ Dataset Preparation  ................................................................................[ADDRESS_1100641]  ............................................................................................................27  
8.3.6 Concentration of Methacholine Required to Reduce FEV 1 by 20% (PC 20) ...............27  
8.3.7 Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second (FEV 1) ........................................27  
8.3.8 Protocol Deviations  .....................................................................................................27  
8.4 Multiple Comparisons  .........................................................................................................27  
8.5 Methods for Handling Missing Data  ...................................................................................27  
8.6 Interim Analyses  .................................................................................................................27  
9. TABLE, LISTING AND FIGURE SHELLS  ............................................................................27  
T16.1.9.1 Summary of Patient Disposition  ...............................................................................29  
T16.1.9.2 Summary of Protocol Deviations ..............................................................................30  
clr_17_08-statistical-methods
Page 6

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 6 of 64 T16.1.9.3 Summary of Patient‚Äôs Treatments Included in the Pharmacodynamic 
Analys is
..............................................................................................................................31  
T16.1.9.4 Summary of Demographic Data and Baseline Characteristics  .................................32  
T16.1.9.5 Summary of Demographic Data and Baseline Characteristics  .................................34  
T16.1.9.6 Summary of Demographic Data and Baseline Characteristics  .................................34  
T16.1.9.7 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV 1 by 20% (PC 20) .........................................................................................................35  
T16.1.9.8 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV 1 by 20% (PC 20) .........................................................................................................35  
T16.1.9.9 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV 1 by 20% (PC 20) .........................................................................................................35  
T16.1.9.10 Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 
second (FEV 1) ...................................................................................................................36  
T16.1.9.11 Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 
second (FEV 1) ...................................................................................................................37  
T16.1.9.12 Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 
second (FEV 1) ...................................................................................................................37  
T16.1.9.13 Overall Summary of Adverse Events  .....................................................................38  
T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_1196]  ............39  
T16.[IP_ADDRESS] Summary of Frequency of Serious Adverse Events by [CONTACT_12360]
 ...................................................................................................................................40  
T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_456827]
 ...................................................................................................................................41  
T16.[IP_ADDRESS] Summary of Frequency of Serious Adverse Events by [CONTACT_470642]
 .........................................................................................................................42  
T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_86945] ................................43  
T16.[IP_ADDRESS] Summary of Frequency of Serious Adverse Events by [CONTACT_86945]  .........................[ADDRESS_1100642]  ........................................................................................57  
L16.2.7.1 Listing of Adverse Events (Safety Population Randomization Period)  ...................58  
L16.2.7.2 Listing of Adverse Events (Safety Population Screening Period)  ............................[ADDRESS_1100643] Results  ..............................................................60  
clr_17_08-statistical-methods
Page 7

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 7 of 64 L16.2.7.4 Listing of Abnormal Physical Examinations
 ............................................................61  
L16.2.8.1 Listing of Vital Signs  ................................................................................................62  
L16.2.8.2 Listing of 12- Lead ECG  ...........................................................................................63  
clr_17_08-statistical-methods
Page 8

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 8 of 64 1. INTRODUCTION  
This Statistical Analysis Plan (SAP) is based on the final Clinical Study Protocol CLR_17_08 
 Study No.  Rev 5.0 dated 08/28/2018 . The SAP provides  details  on the 
planned statistical  methodology for the analysis of the study data. The SAP also outlines the 
statistical programming specifications for the tables, listings and figures.  
This SAP describes  the study endpoints, derived variables,  anticipated  data transfor mations and  
manipulations, and other details  of the analyses  not provided in the study protocol. This SAP 
there fore outlines in detail all other aspects  pertaining to the planned  analyses and  
presentations for this  study.  
The following  docum ents were  reviewed  in preparation  of this SAP:  
‚Ä¢ Final Clinical Study Protocol CLR_17_08 (  Study No.  Rev 5.0 dated 
08/28/2018 
‚Ä¢ The final Electronic Case Report Form ( eCRF ) specification  for  Study No. 
 
The reader  of this SAP is enco uraged to  also read the clinical protocol for details  on the 
conduct of this study,  and the operational aspec ts of clinical  assess ments and timing for 
completing  a patient  in this study.  
2. OBJECTIVES  
The objectives of this study are to: 
1. Demonstrate the pharmacodynamic equivalence of the Test formulation of albuterol  sulfate 
inhalation aerosol, eq 90  mcg base ( Sun Pharmaceuticals Industries Limited ) to the marketed 
product PROAIR¬Æ HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva 
Respi[INVESTIGATOR_696], LLC) using methacholine bronchoprovocation in subjects with s table, mild 
asthma based on National Asthma Education and Prevention Program (NAEPP) guidelines. 
2. Compare the safety of Test, low -dose Reference, high -dose Reference, and Placebo 
treatments in subjects with stable, mild asthma based on NAEPP guidelines.  
3. OVERALL STUDY DESIGN  
This randomized, single -dose, double -blind, double -dummy, four -period, four -sequence, four -
treatment, Placebo and active controlled, comparative, multiple -center, crossover -design 
bronchoprovocation study  has been designed to evaluate the pharmacodynamic equivalence of 
albuterol sulfate HFA inhalation aerosol, eq 90  mcg base per inhalation ( Sun Pharmaceuticals 
clr_17_08-statistical-methods
Page 9

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol         
        
Protocol / Study No.  CLR_17_08 
/  
 
12/21/2018                 
ÔÇ°
 
Sun Pharmaceuticals Industries Limited
 
ÔÇ°
             
Page 
9 
of 
64 Industries Limited ) to PROAIR¬Æ HFA (albuterol sulfate) Inhalation Aerosol, eq 90  mcg base per 
inhalation (Teva Respi[INVESTIGATOR_696], LLC) 
in subjects with stable, mild asthma.
 
Approximately [ADDRESS_1100644] 6 months before Screening.  
Randomized subjects who withdraw from the study will not be replaced. 
Before any study -specific procedures are performed, all subjects will read and sign the IRB -
approved informed consent form. 
Eligible subjects will complete 5 clinic visits as follows: 
 
‚Ä¢
 
Visit 1: Screening (Day -14 to -1) 
‚Ä¢
 
Visit 2: Period 1  
‚Ä¢
 
Visit 3: Period 2  
‚Ä¢
 
Visit 4: Period 3  
‚Ä¢
 
Visit 5: Period [ADDRESS_1100645] of three to four acceptable curves obtained at each 
time point. FVC and FEV 1/FVC ratio [(FEV 1/FVC) x 100] will also be recorded along with 
FEV 1 measurements at each visit.  
Screening  
Screening evaluations will be performed in accordance with the study calendar. Clinical 
assessments will include: vital sign measurement, height, weight, physical examination, urine 
pregnancy test ( for all women  of childbearing potential), 12 
-
lead electrocardiogram (ECG), and 
pulse oximetry (during methacholine bronchoprovocation challenges). Chest x -ray may be 
performed at discretion of the Investigator. Qualifying FEV [ADDRESS_1100646] be  ‚â• 80% of 
predicted value. Once Qualifying FEV [ADDRESS_1100647] -saline FEV 1 should not drop more than 10% from pre -saline FEV 1 and 
should be ‚â• 70% of predicted value . If the subject fails to meet any of  these requirements, the 
procedures must be stopped, rescue albuterol administered, and the visit should be rescheduled. 
All clinical assessments except height and weight will be performed at each rescheduled visit. 
Subjects who fail three consecutive visi ts will not be eligible to participate in the study. Subjects 
meeting post -saline FEV 1 criteria will undergo methacholine bronchoprovocation challenge with 
clr_17_08-statistical-methods
Page 10

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100648]‚Äôs baseline provocation 
concentratio n of inhaled methacholine required to reduce FEV 1 by 20% (PC 20) relative to the 
post- saline value. The maximum concentration of methacholine to be administered in this step 
will be 8 mg/mL. Subjects who do not respond to methacholine doses at or below 8  mg/mL will 
not be eligible for enrollment in the study.  
Once the methacholine challenge test is completed, rescue albuterol will be administered and 
spi[INVESTIGATOR_460354] [ADDRESS_1100649]‚Äôs FEV 1 returns to 
within 90% of  the best post -saline FEV [ADDRESS_1100650] dosing visit will occur no earlier 
than 24 hours and no more than 14 days after Screening procedures and the interval (washout 
period) between dosing visits should be at least 48 hours. At each treatment visit, the following 
will be perfo rmed before dosing: 
‚Ä¢ Vital sign measurement  
‚Ä¢ 12-lead electrocardiogram (ECG) as the discretion of the Investigator after the initial 
Screening visit  
‚Ä¢ Pulse oximetry (during methacholine bronchoprovocation challenges) 
‚Ä¢ Concomitant medication update (confirming washouts)  
‚Ä¢ Adverse Events (AE) review  
‚Ä¢ Urine pregnancy test for all women of childbearing potential 
A pre -treatment evaluation will be performed. This will confirm that pre -challenge FEV 1 is ‚â• 
80% of predicted and within 88 and 112% of qualifying spi[INVESTIGATOR_798091]. 
After the first inhalation of saline control is administered, the FEV 1 should not drop more than 
10% compared to pre -challenge value and should be ‚â• 70% of the predicted value. I f the subject 
fails to meet any of these requirement s, the procedures must be stopped, albuterol administered, 
and the visit should be rescheduled. Subjects who fail three consecutive visits should be dropped 
from the study. 
Subsequently, review of inhaler dosing technique, priming and preparation of inhalers will be 
performed. The subject will receive one of the four randomized study treatments. The time of 
last actuation will be recorded, as well as the adequacy of inhaler t echnique. Approximately 15 
clr_17_08-statistical-methods
Page 11

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100651] inhalation of study treatment, a methacholine bronchoprovocation 
challenge will be given with progressive concentrations to determine the PC 20. The 20% 
reduction in FEV [ADDRESS_1100652] obstruction and subjects will be 
followed until FEV 1 returns to within 90% of the best FEV [ADDRESS_1100653] x -
rays, and methacholine administratio n do not need to be performed. 
The spi[INVESTIGATOR_798092]. The maximum methacholine  dose administered will be 8 mg/mL at Screening 
and 128 mg/mL for treatment visits.  
  
clr_17_08-statistical-methods
Page 12

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 12 of 64  
Figure 1: Study Schematic  
Procedures  Visit 1 
Visit 2 
Visit 3 
Visit 4 
Visit 5 
Screening  Period 1 Period 2 Period 3  Period 4  
End of Study  
Informed Consent  X     
Baseline Demographics  X     
Medical History  X     
Vital Signs*  X X X X X 
Height and Weight  X     
Physical Exam  X    X 
Urine Pregnancy Test** X X X X X 
12-Lead ECG  X X‚Ä† X‚Ä† X‚Ä† X‚Ä† 
Chest X -Ray‚Ä° X     
Concomitant Medication  X X X X X 
Spi[INVESTIGATOR_038] (FEV 1 and FVC)¬ß X X X X X 
Saline Control Administration  X X X X X 
Methacholine Challenge  X X X X X 
Pulse Oximetry  X X X X X 
Inclusion/Exclusion Criteria 
Review X     
Prime, dispense study product and 
instructions   X X X X 
Dosing«Å  X X X X 
Assessment of Compliance   X X X X 
Adverse Events  X X X X X 
Provide Diary  X X X X  
Collect /Review Diary   X X X X 
Schedule next visit  X X X X 
 
* Vital signs will be measured before and after methacholine bronchoprovocation challenges at all visits.  
** Female subjects of childbearing potential.  
‚Ä† 12-lead ECG to be performed at Screening may be repeated before methacholine bronchoprovocation challenges 
at discretion of Investigator.  
‚Ä° Chest X -ray is to be performed at discretion of Investigator.  
¬ß FEV [ADDRESS_1100654] from four different inhalers (each dose from a separate inhaler).  
clr_17_08-statistical-methods
Page 13

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100655]  
The following products will be used in the study: 
Test (T active) : Albuterol Sulfate Inhalation Aerosol, eq 90  mcg base per inhalation ( Sun 
Pharmaceuticals Industries Limited ) 
Reference (R active) : PROAIR¬Æ HFA (albuterol sulfate) Inhalation Aerosol, eq 90  mcg base per 
inhalation (Teva Respi[INVESTIGATOR_696], LLC) 
Test Placebo (T Placebo) : Placebo for Albuterol  Sulfate Inhalation Aerosol (i.e., vehicle 
canister with T active actuator [ Sun Pharmaceuticals Industries Limited ]) 
Reference Placebo (R Placebo) : Placebo for Albuterol Sulfate Inhalation Aerosol (i.e., vehicle 
canister with R active actuator [ Sun Pharmac euticals Industries Limited ]) 
 
Treatments will be as follows:  
Treatment A: Zero -dose 
Two different Reference Placebo inhalers and two 
different Test Placebo inhalers  
1 puff Inhaler 1 
1 puff Inhaler 2 
1 puff Inhaler 3 
1 puff Inhaler 4 
Treatment B: [ADDRESS_1100656] Placebo inhalers  1 puff Inhaler 1  
1 puff Inhaler 2 
1 puff Inhaler 3 
1 puff Inhaler 4 
Treatment C: [ADDRESS_1100657] 
Placebo inhalers  1 puff Inhaler 1 1 puff Inhaler 2 
1 puff Inhaler 3 
1 puff Inhaler 4 
Treatment D: [ADDRESS_1100658] Placebo inhaler, and two 
different Reference Placebo inhalers  1 puff Inhaler 1 1 puff Inhaler 2 
1 puff Inhaler 3  
1 puff Inhaler 4 
 
5. RANDOMIZATION AND BLINDING  
At Visit 1 eligible subjects will be enrolled in the study, and scheduled for Visit 2. At Visit 2, 
eligible subjects will be randomized to one of the four sequences as shown below. Treatments 
clr_17_08-statistical-methods
Page 14

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100659] ‚ÄòTreatment Box‚Äô assigned to the subject. A perforated or two -part label 
will be attached to each of the small boxes containing individual inhalers. Both pie ces of the 
label should include the following information: Protocol number, randomization number, space 
for subject‚Äôs initials, statement that the study product is for Investigational Use only, space for 
dispensing date and the Sponsor‚Äôs name. In addition all subjects will be provided with written 
instructions on how to use the study medication. One part of the label will remain attached to the 
box. The other part will be removed before dispensing and attached to the study product log. 
The Investigator, staff at the study site, study monitors, and data analysis/management personnel 
will be blinded to the patient assignment.  
6. SAMPLE SIZE  
The sample size estimation for this study was based on data from the study by [CONTACT_798098]. 
that reported the bronchopr otective effect of inhaled salbutamol (albuterol) on methacholine 
PC 20FEV 1.  
clr_17_08-statistical-methods
Page 15

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100660] coefficient of variability (COV) value for ln -transformed PC 20 was 
estimated as 0.846 from the mean ratio and SD values for the PC 20 at the 200 and 100 mcg doses 
(Table 1 in reference 2). Based on this COV, 98 evaluable subjects would be required in the PD 
population to demonstrate pharmacodynamic equivalence (i.e., 90% confidence interval on 
relative bioavailability [F] is within the bioequivalence limit s of 0.67 to 1.50) with 90% power 
for a crossover study, assuming a true ratio of F = 1.1. To allow for approximately 20% of 
subjects that may discontinue from the study or have major protocol violations, and therefore not 
qualify for the PD population, up to 123 subjects will be randomized in the study.  
7. STUDY POPULATIONS  
Per-Protocol ( PP) Population 
The PP population will include all subjects  who: 
‚Ä¢ Completed all four randomized treatment periods  with an evaluable PC 20FEV 1 in each 
period. 
‚Ä¢ Were compliant with study treatment dosing procedures. 
‚Ä¢ Did not use any restricted concomitant medications.  
‚Ä¢ Did not have any other significant protocol deviations. 
Pharmacodynamic (PD) Population 
The PD population used in the dose- scale analyses will include subjects  who: 
‚Ä¢ Completed at least one of the four randomized treatment periods  with an evaluable 
PC 20FEV 1. 
‚Ä¢ Were compliant with study treatment dosing procedures. 
‚Ä¢ Did not use any restricted concomitant medications.   
‚Ä¢ Did not have any other significant protocol deviations. 
Safety Populations 
The Safety population will include all subjects who administered at least one actuation of any of 
the four investigational products (Test, Reference, Test Placebo, Reference Placebo) in any of 
the four randomized treatment periods. 
PP and PD populations will be shortlisted upon a blinded review of the data by [CONTACT_798099].  
clr_17_08-statistical-methods
Page 16

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100661]  statistical  practice,  the significance  threshold is set to  p < 0.05 ( two-
tailed ). Data will be summarized with respect to demographic and baseline characteristics and 
safety variables.  
For categorical variables  and non- missing data , the number and percent of each category within 
a parameter will be calculated. For continuous variables, stati stics will include n, mean, standard 
deviation, median, minimum and maximum values.  
All statistical analyses will be conducted using Statistical Analysis System ( SAS¬Æ, version 9.4 or 
higher).  
  
 
 
8.[ADDRESS_1100662] demographic characteristics will be summarized separately in the PP, PD 
and Safety populations: 
‚Ä¢ Age (years)  
‚Ä¢ Sex (male/female)  
‚Ä¢ Ethnicity (Hispanic/non- Hispanic)  
‚Ä¢ Race (White, Black/African American, Native Hawaiian or Other Pacific Islander, 
Asian, American Indian or Alaska Native) 
‚Ä¢ Tobacco use (yes/no) 
‚Ä¢ Number of years patient suffered from symptoms caused by [CONTACT_4221] 
‚Ä¢ Qualifying spi[INVESTIGATOR_038]  (Visit 1, Pre- and Post- saline)  
‚Ä¢ PC 20 FEV 1 at Visit 1  
clr_17_08-statistical-methods
Page 17

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 17 of 64 Continuous variables will be summarized using descriptive statistics (n, mean, standard 
deviation, median, minimum, maximum) ; categorical variables will be  described  in frequencies 
and percentages. Summary tables will be  included. 
All data will be listed by [CONTACT_4676].  
8.1.[ADDRESS_1100663]  their current and  recent  (‚â§ 6 months)  medication use. 
During all subsequent visits , subjects  will be ask ed about ongoing and new concom itant 
medication s.  
All prior and conco mitant medicati ons will be  listed by [CONTACT_4676].  
8.2 Pharmacodynamic Equivalence Analyses 
Pharmacodynamic (PD) equivalence between Test and Reference will be based on the dose -scale 
method of analysis of the post -dose PC 20 (mg/mL) data using non -linear E max modeling, as 
outlined in the FDA Draft Guidance on Orlistat capsule (
3
). Alternative models may be tested if  
warranted by [CONTACT_26739], and these models as well as the specific criteria related to their use, are 
described in more detail in Section 8.2.7. 
8.2.[ADDRESS_1100664] -dose PC 20, which is the p rovocative 
concentration of methacholine challenge agent required to reduce the forced expi[INVESTIGATOR_798093] (FEV 1) by 20%, following the administration of different doses of albuterol (or 
placebo) by [CONTACT_12699].  
The 20% reduction in FEV [ADDRESS_1100665] -saline FEV 1 measure before 
placebo or albuterol administration. The methacholine PC 20 will be calculated by [CONTACT_798100] % decrease in FEV [ADDRESS_1100666] a 20% decrease in FEV 1. This 
interpolation will be based on log transformed methacholine concentrations. In the event that 
subjects receiving the maximum concentration of methacholine (128  mg/mL) at an y dosing visit 
(Visits 2 -5) do not achieve at least a 20% fall in FEV 1, then they will have their PC 20FEV 1 data 
recorded as > 128 mg/mL and the data from that visit will be excluded from the statistical 
analysis; the data from the other Visits for these subjects will be eligible for inclusion in the PD 
clr_17_08-statistical-methods
Page 18

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100667] -specific guidance for albuterol s ulfate  explains that  ‚Äúlog transformation of the 
PD data before fitting the Emax model is recommended for dose -scale analysis ‚Äù (
4
); however, 
this guidance does not specify  which log transformation should be used.  Therefore, the PC 20 
values will  be transformed  using the  reported  Log 2 method ( 5 , 6 ), prior to NONMEM¬Æ dataset 
construction. 
 
  
The datasets will include i ndividual albuterol dosing information  and PC20 data. The actual 
dosing amount per treatment  period will be used. Formulation will also be entered in the dataset. 
These will be entered as [ADDRESS_1100668]. The placebo dose 
will also be considered as the reference formulation. The dose amount for the placebo treatment 
will be set to 0. Data will be excluded from the analysis if insufficient or inaccurate  dosing 
information are recorded.  
8.2.5 Dose-Scale Approach  
To assess bioequivalence using PD endpoints, t he FDA albuterol- specific guidance  (
4
) 
recommends using the  dose- scale approach described  in FDA‚Äôs orlistat guidance (
3
). This 
approach involves fitting dose-response data using the following equation: 
Equation 1 
relrel
F Dose EDF Dose EE‚ãÖ +‚ãÖ ‚ãÖ+ =
500maxResponse  
In Equation 1, the response is the measured PC 20, E [ADDRESS_1100669] and reference 
products. 
The FDA  orlistat  guidance allows for the dose -scale Emax model to be fitted either to the mean 
or to the individual scores of dose response data. The analysis described in this plan will be 
clr_17_08-statistical-methods
Page 19

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100670] in a 
bioequivalence (BE) cro ssover trial.  
The PC 20 data w ill be  analyzed based on a two -step dose-s cale analysis to estimate F rel: 
‚Ä¢ Firstly, a dose -response relationship w ill be  mathematically described by [CONTACT_798101]- response data , and an estimate for F rel will be  
obtained. 
‚Ä¢ Secondly, a 90% confidence interval for F rel will be  estimated by [CONTACT_798102]'s ( 7 ) bias-
corrected and accelerated (BCa) method.  
8.2.6 Dose Response Emax Model 
The analysis will use the FDA recommended Emax model  using NONMEM¬Æ. The model will 
include the following: 
‚Ä¢ Etas will be included on PD parameters E0, Emax and ED 50, coded as Theta(x)+Eta(x) 
for E 0 and Emax and as Theta(x)*exp(Eta(x)) for ED 50. 
‚Ä¢ The possibility of adding an eta on the F rel parameter will be tested. . 
‚Ä¢ A combination of proportional and additive residual error (Epsilons).  
Additionally, the model may be simplified by [CONTACT_798103] (Etas or Epsilons) if 
they are estimated  to be close to the boundary ( e.g., 0). 
Quality of fit and selection of an alternate model will be determined using the objec tive function. 
A lower objective function is preferred if a model has the same number of parameters. 
Otherwise, the model will be chosen according to  the difference in the MOF based on a Chi -
square distribution ( p < 0.01 will be considered significant) , taking the difference in the numbers 
of fitted parameters  into account . Throughout the modeling process, the first -order conditional 
estimate (FOCE) option in NONMEM will be used.  
8.2.7 Alternative Approach  to the Dose Response Emax Model  
The Emax  model (as described in Sections 8.2.5 and 8.2.6) is the model described by [CONTACT_798104] (
3
) and is the preferred one.  However , based on the results of this Emax 
model, further analysis may be required. More specifically, an alternate approach will be used to 
re-analyze the data if the following 2 criteria are met:  
‚Ä¢ If the predicted response of the low-dose and high-dose of albute rol fall within 20 -80% of 
the maximum response. 
‚Ä¢ If the predicted response for the low -dose of albuterol is ‚â• 75% of the predicted response 
for the high- dose albuterol.  
clr_17_08-statistical-methods
Page 20

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 20 of 64 Therefore, if the Emax  model previously described in this section is appropriate at describing the 
PC 20 data, it will be used and will be considered final. However, if this Emax model is 
considered inappropriate (based on criteria listed above), the alternative modeling approac h will 
be used as described below.  
The relationship between dose and response can often be described by a hyperbolic curve that is 
defined by [CONTACT_12801], often called the ‚ÄúEmax model‚Äù:  
Equation 2 ùëÖùëíùë†ùëùùëúùëõùë†ùëí =ùê∏ùëöùëéùë•‚àôùê∑ùëúùë†ùëí
ùê∑ùëúùë†ùëí+ùê∑50 
 
This relationship is depi[INVESTIGATOR_48393], in Figure 1.  
Figure 1. Example of Emax Dose- Response Relationship  
 
In theory, a minimum of two observations are required to estimat e the two model parameters 
(Emax and D 50). Ideally, these two data points should be as far apart as possible, and lie close to 
the inflection points on the curve , to properly characterize Emax and D 50. This ideal scenario is 
depi[INVESTIGATOR_6517] 2 ; with the predicted Emax curve in black, observed data represented by [CONTACT_798105] , and their associated error shown by [CONTACT_798106]‚Äôs  cente r. 
  
clr_17_08-statistical-methods
Page 21

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100671] s the  ideal  scenario; however, in practice  the data points may not always lie this  
far apart.  If these two data points are too close to one and other,  Emax and ED 50 estimations can 
be more difficult and less certain.  
In other words, different Emax relationships, or combinations of parameter estimates (Emax and 
ED 50), could explain the same data points ; therefore , it becomes more difficult to know with 
certainty which relationship reflects reality.  This problem is illustrated in Figure 3, where very 
different Emax  curves (denoted by [CONTACT_798107], blue and yellow lines) all pass through the same 
two observed data points (red points with vertical error bars). 
  
clr_17_08-statistical-methods
Page 22

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 22 of 64 Figure 3. Example of Possible Emax Curves for the Same Data Points  
 
If the response data associated with the two doses (90 mg and 180 mg) are close to one an d 
other, which is analogous to the scenario depi[INVESTIGATOR_6517] 3, this proximity of the data will 
make it difficult to properly estimate the parameters Emax and ED 50. 
In such cases, log -transformation of the independent variable (dose) can be beneficial.  The log 10 
transformation of dose is used in such analys es. Despi[INVESTIGATOR_798094], 
it is recognized that when the data on the X -axis are log -transformed, the relationship becomes 
more  linear, especially between doses that are associated with 20% and 80% of Emax.  (
8
); this is 
illustrated in Figure 4.  
  
clr_17_08-statistical-methods
Page 23

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 23 of 64 Figure 4.  Depi[INVESTIGATOR_798095]- Linear Dose -Response Relationship  
 
When using a log -linear model, the relationship between log(dose) and response can be 
described by a straight -line between 20% and 80% of the maximum effect. Consequently , it is  no 
longer necessary to estimate Emax and ED 50 parameters, thereby [CONTACT_798108].  Instead, the relationship between log(dose) and 
response can be described by a simple slope and intercept. 
It can also be appreciated from Figure  4 that when using the log -linear model, the intercept (the 
hypothetical response at dose zero based on a linear relationship) is not equivalent to  the E 0 that 
is associated with the Emax model.  Therefore, response data associated with the placebo should 
not be fitted by [CONTACT_63450] -linear model for two reasons: 
1) Linearity only applies to doses that are associated with responses that are between 20% 
and 80% of the maximal response.  By [CONTACT_108], this excludes a dose of zero that is not 
associated with a respo nse.  
2) Inclusion of placebo data would falsely bias the estimation of the intercept parameter, and 
the slope that would be fitted by [CONTACT_798109].  Other 
parameter estimates (such as F rel) will also be unreliable.   
For the rea sons above, the placebo data should not be fitted in the log -linear model.  In such an 
analysis, only response data associated with the [ADDRESS_1100672].  
clr_17_08-statistical-methods
Page 24

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 24 of 64 Therefore, in this alternate model, PC 20 would be fitted according to the following equation: 
Equation 3  ùëÖùëíùë†ùëùùëúùëõùë†ùëí =ùêºùëõùë°ùëíùëüùëêùëíùëùùë° +ùëÜùëôùëúùëùùëí‚àóùê∑ùëúùë†ùëí‚àóùêπùëüùëíùëô 
In this relationship, both response and dose are log- transformed.  
The analysis using the Emax  model detailed in the previous section will be presented for 
information purposes only even if this alternative approach is used. 
8.2.8 Bootstrap 
In the FDA orlistat guidance  (
3
), 90%  CI are constructed using a nonparametric bootstrap 
technique. Essentially, subjects are repeatedly sampled at random with replacement, creating 
new datasets of the same size as the original dataset  and new PD parameters are estimated using 
the same final model .  Ten thousand ( 10 000) of these bootstrap samples will be  constructed and 
NONMEM¬Æ analyses will be  performed on al l.  A matrix of bootstrap mean population estimates 
(Frel) will thus be obtained  ( 9 ). Only the bootstrap for successful NONMEM¬Æ analyses will be 
used to build the 90% CI. 
Bootstrappi[INVESTIGATOR_798096]¬Æ version WFN7 . 
8.2.9 Calculation of Confidence Intervals for Frel  
The bias -corrected and accelerated (BCa) method for constructing the 90% CI for F rel will be 
employed as described in the FDA guidance for orlistat (
3
), using the formulae described by 
[CONTACT_798110] & Tibshirani (
7
). 
The BCa interval of intended coverage 1 -2Œ± is given by [INVESTIGATOR_8850] 4, where( )1ÀÜŒ±Œ∏‚àóand ( )2ÀÜŒ±Œ∏‚àóare the 
100¬∑Œ±1th and 100¬∑Œ±2th percentiles of the B bootstrap replications, respectively.  The variables Œ±1 
and Œ±2 are defined in Equations 5 a and 5b. 
Equation 4 ( ) ( )( )2 1ÀÜ,ÀÜ:Œ± Œ±Œ∏ Œ∏‚àó ‚àó
aBC  
Equations 5a ( )
( )( )Ô£∑Ô£∑
Ô£∏Ô£∂
Ô£¨Ô£¨
Ô£≠Ô£´
+ ‚ãÖ ‚àí++ Œ¶ =Œ±Œ±
Œ±z z az zz
00
0 1ÀÜÀÜ1ÀÜÀÜ 
Equation 5b ( )
( )( )Ô£∑Ô£∑
Ô£∏Ô£∂
Ô£¨Ô£¨
Ô£≠Ô£´
+ ‚ãÖ ‚àí++ Œ¶ =‚àí‚àí
Œ±Œ±
Œ±1
01
0
0 2ÀÜÀÜ1ÀÜÀÜz z az zz 
clr_17_08-statistical-methods
Page 25

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 25 of 64 In Equations 5a and 5b, Œ¶(¬∑) represents  the standard normal cumulative distribution function and 
z(Œ±) is the 100¬∑ Œ±th percentile point of a standard normal distribution. The variables aÀÜand 0ÀÜz 
represent acceleration and bias -correction, respectively.  They are computed as described by 
[INVESTIGATOR_185560] 6 and 7. 
 
Equation 6 ( ){ }
Ô£∑Ô£∑
Ô£∏Ô£∂
Ô£¨Ô£¨
Ô£≠Ô£´ <Œ¶ =‚àó
‚àí
BbzŒ∏ Œ∏ÀÜ ÀÜ #ÀÜ1
0  
Equation 7 ( ) ( )( )
( ) ( )( ){ }23
1213
ÀÜ ÀÜ 6ÀÜ ÀÜ
ÀÜ
‚àë‚àë
=‚ãÖ=‚ãÖ
‚àí‚àí
=
n
i in
i ia
Œ∏ Œ∏Œ∏ Œ∏
 
In Equation 6, Œ¶-1(¬∑) indicates the inverse function of a standard normal cumulative distribution 
function.  The numerator represents the number of bootstrap values ( )b‚àóŒ∏ÀÜ  that are les s than the 
original estimate of Œ∏ÀÜ.  B is the number of bootstrap replicates. 
Equation 7 uses ( )‚ãÖŒ∏ÀÜ and ( )iŒ∏ÀÜ, which are the average value s of all jackknife replications and the ith 
jackknife replication of Œ∏ÀÜ, respectively.  
The calculation of the BCa interval w ill be  performed with the code provided by [CONTACT_798110] & 
Tibshirani (
10
), using S-Plus for Windows¬Æ. 
8.2.[ADDRESS_1100673] formulation will be declared bioequivalent to the reference formulation if the estimate d 
Frel and the 90% CI are completely contained within the range of 67.00 to 150.00%.    
8.[ADDRESS_1100674] one actuation of any of the study products (Safety 
Population ) will be included in the comparative safety analysis.  
8.3.1 Adverse Events 
All the adverse events (AEs) reported throughout the study will be coded and classified 
according to the MedDRA (Medical Dictionary for Regulatory Activities) coding  dictionary 
clr_17_08-statistical-methods
Page 26

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 26 of 64 (Version 20.0 or higher). Each adverse event is to be evaluated for date of start and end, 
seriousness, severity, causal relationship with the study drugs, action taken and outcome. 
A summary table of the number and percent of subjects  with AEs by [CONTACT_57501] o rgan class, 
preferred term , will be presented. Each patient will be counted only once within each preferred 
term.  Other summaries may be added based on the data obtained. 
A frequency summary table of the number of AEs by [CONTACT_9313], preferred term, and 
severity will be presented. Severity will be classified as ‚ÄúMild‚Äù, ‚ÄúModerate‚Äù or ‚ÄúSevere‚Äù.  
Similarly, a frequency summary table of the number of AEs by [CONTACT_9313], preferred 
term, and relationship to a study drug will be presented. Relationship to a study drug wi ll be 
classified as ‚ÄúNot Related ‚Äù or ‚ÄúRelated ‚Äù where causality ‚ÄúCertain, Probable and Possible‚Äù will be 
assessed as ‚ÄúRelated‚Äù while ‚Äú Unlikely and Unrelated‚Äù will be assessed as ‚ÄúNot Related‚Äù . 
A frequency summary table of the number of SAEs by [CONTACT_9313], preferred term  will 
also be presented by [CONTACT_1570]. 
If sufficient data exist, AEs frequencies will be compared among treatments using Fisher‚Äôs exact 
test. If the overall Fisher‚Äôs exact test is significant for comparisons across the 4 treatments,  pair-
wise testing between treatments will be conducted to determine which contrasts are significant.  
All AEs will be listed by [CONTACT_798111] .  
8.3.2 Vital Signs 
At each clinic visit,  subjects ‚Äô vital signs (pulse, BP, temperature , and r espi[INVESTIGATOR_1487] ) will be 
recorded before and after methacholine procedures. 
Descriptive sum maries (nu mber of observati ons, m ean, standard  deviation, mini mum, m edian  
and maximum) will  be provided by [CONTACT_12268] . 
All data will be listed by [CONTACT_4676].  
8.3.3 Physical Exam 
At Visits 1 and 5 , the Investigator will perform a general physical exam for each qualified 
patient ; any significant findings will be noted. At minimum , the physical exam must include a 
head, ear, eyes, nose, lungs and throat examination.  
Any abnormal physical exam results  will be listed by [CONTACT_69867].  
8.3.4 12-lead ECG  
Subjects  will undergo a 12 -lead ECG at Screening. An ECG may be performed at subsequent 
visits at the Investigator`s discretion . Any clinically significant findings will be noted. 
clr_17_08-statistical-methods
Page 27

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page [ADDRESS_1100675]  results will be listed by [CONTACT_69867].  
8.3.6 Concentration  of Methacholine Required to Reduce FEV 1 by 20% (PC20) 
Descriptive sum maries (nu mber of observati ons, m ean, standard  deviation, mini mum, m edian  
and maximum) will  be provided separately  for PC 20 by [CONTACT_798112] , PD  and Safety 
Population. 
8.3.7 Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second  (FEV1) 
Descriptive sum maries (nu mber of observations, m ean, standard deviation, minimum, m edian  
and maximum) will  be provided separately  for pre-challenge FEV 1 by [CONTACT_798113] , PD and 
Safety Population. 
8.3.8 Protocol Deviations 
The total number of subjects  with protocol deviation, the total number of protocol deviations as 
well as protocol deviation categories will be summarized.  
Protocol deviations will be listed by [CONTACT_4676].  
8.4 Multiple Comparisons 
No multiple comparison adjustment will be made in this study.  
8.5 Methods for Handling  Missing Data 
Each demographic and baseline characteristic variable will be analyzed using all available data. 
Thus, s ubjects  with missing data will only be excluded from analyses for which data are not 
available.  
8.6 Interim Analyses 
No interim analys es are planned for this study.  
9. TABLE, LISTING AND FIGURE SHELLS  
The following shells are included to provide a framework for display ing data in the final clinical 
study report . These shells  are meant to  provide a  general layout f or final Tables, Listings and 
Figures ; therefore, they may not reflect every aspect of the current  study. 
Tables, Listings and Figures are numbered in accord ance with  the ICH structure. Following data 
clr_17_08-statistical-methods
Page 28

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                 Protocol / Study No.  CLR_17_08 /  
 
12/21/2018                 ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°             Page 28 of 64 analyses , table headers, variables names and footnotes will be modified as needed.  
Descriptive and inferential statistical (including bootstrap) analyses will be performed using 
SAS¬Æ statistical software version 9.4 or higher and NONMEM¬Æ, unless otherwise noted. 
clr_17_08-statistical-methods
Page 29

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 29 of 64 T16.1.9.1 Summary of Patient Disposition  
Subjects  
Overall 
(n (%)) 
Subjects Screened  xx 
Subjects Randomized  xx 
Safety Population  xx 
Completed Study  xx (xx.x)  
Terminated Early  xx (xx.x)  
    Adverse Event  xx (xx.x)  
    Lack of Efficacy  xx (xx.x)  
    Lost to follow -up xx (xx.x)  
    etc. xx (xx.x)  
 xx (xx.x)  
     Other  xx (xx.x)  
 
                                                                   % is based on total number of subjects  in the safety population . 
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 30

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 30 of 64 T16.1.9.2 Summary of Protocol Deviations 
(Safety Population) 
  
Total 
N = xx 
Total Subjects  with Protocol Deviations  xx 
Total Deviations  xx 
    Assessment conducted out of window  xx 
    Lost to Follow -up xx 
    Missed Visit  xx 
    Non-compliance with study drug  xx 
    Non-compliance with study procedures  xx 
    Restricted Medication  xx 
    etc. xx 
     xx 
    Other  xx 
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 31

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 31 of 64 T16.1.9.3 Summary of Patient‚Äôs Treatments Included in the Pharmacodynamic Analysis  
 
 
Patient 
Screen  
Number Patient 
Randomization   
Number Sequence  
Treatment A  Treatment B   
Treatment C   
Treatment D  
xx-xxxx  
 xx-xxxxx  
 1 
 Yes Yes 
 Yes No 
       
       
       
       
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 32

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 32 of 64 T16.1.9.4 Summary of Demographic Data and Baseline Characteristics  
(Safety Population) 
  Total 
N = xx 
Age (years)  n xx 
 Mean ¬± SD  xx.x ¬± x.x  
 Median  xx.x 
 Range  xx-xx 
Race  (n (%))  American Indian or Alaska Native  xx (xx.x)  
 Asian  xx (xx.x)  
 Black/African American  xx (xx.x)  
 Native Hawaiian or other Pacific Islander  xx (xx.x)  
 White  xx (xx.x)  
 Other  xx (xx.x)  
Ethnicity  (n (%))  Hispanic or Latino  xx (xx.x)  
 Not Hispanic or Latino  xx (xx.x)  
Gender  (n (%))  Female  xx (xx.x)  
 Male  xx (xx.x)  
Tobacco use  (n (%))  Yes xx (xx.x)  
 No xx (xx.x)  
Number of  years patient has suffered 
from symptoms caused by [CONTACT_4221]  
 n xx 
 Mean ¬± SD  xx.x ¬± x.x  
 Median  xx.x 
 Range  xx-xx 
                   
 
clr_17_08-statistical-methods
Page 33

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 33 of 64   Total 
N = xx 
   
FEV 1 (L) (Pre-saline)  n xx 
 Mean ¬± SD  xx.x ¬± x.x  
 Median  xx.x 
 Range  xx-xx 
FEV 1 (L) (Post -saline)  n xx 
 Mean ¬± SD  xx.x ¬± x.x  
 Median  xx.x 
 Range  xx-xx 
PC 20 FEV 1 (mg/mL)  n xx 
 Mean ¬± SD  xx.x ¬± x.x  
 Median  xx.x 
 Range  xx-xx 
   
        
  N= number of subjects  in the safety population ; n= number of subjects  with data available; % is based on N  
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 34

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 34 of 64  
Similar table will be created for:  
T16.1.9.5 Summary of Demographic Data and Baseline C haracteristics  
(Pharmacodynamic Population) 
 
T16.1.9.6 Summary of Demographic Data and Baseline C haracteristics  
(Per-Protocol Population ) 
  
clr_17_08-statistical-methods
Page 35

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 35 of 64  
T16.1.9.7 Summary of Concentration (mg/mL) of Methacholine Required to Reduce FEV 1 by 20% (PC20) 
(Safety Population) 
Statistic Treatment A  
N = xx Treatment B  
N = xx Treatment C  
N = xx Treatment D  
N = xx 
n xx xx xx xx 
Mean ¬± SD  xxx.x ¬± xx.x  xxx.x ¬± xx.x  xxx.x ¬± xx.x  xxx.x ¬± xx.x  
Median  xxx.x  xxx.x  xxx.x  xxx.x  
Range  xxx.x ‚Äì xxx.x xxx.x ‚Äì xxx.x xxx.x ‚Äì xxx.x xxx.x ‚Äì xxx.x 
     
     
 
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
T16.1.9.8 Summary of Concentration (mg/mL) of Methacholine Required to Reduce FEV 1 by 20% (PC20) 
(Pharmacodynamic Population) 
T16.1.9.9 Summary of Concentration (mg/mL) of Methacholine Required to Reduce FEV 1 by 20% (PC20) 
(Per-Protocol Population ) 
 
  
clr_17_08-statistical-methods
Page 36

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 36 of 64 T16.1.9.10 Summary of Pre-challenge  Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second  (FEV1) 
(Safety Population) 
Visit Statistic Overall 
Visit 1  (Pre-saline)  N xx 
 Mean ¬± SD  xxx.x ¬± xx.x  
 Median  xxx.x  
 Range  xxx.x ‚Äì xxx.x 
Visit 1 (Post -saline)  N xx 
 Mean ¬± SD  xxx.x ¬± xx.x  
 Median  xxx.x  
 Range  xxx.x ‚Äì xxx.x 
   
Visit 2  (Pre-saline)  N xx 
 Mean ¬± SD  xxx.x ¬± xx.x  
 Median  xxx.x  
 Range  xxx.x ‚Äì xxx.x 
   
Visit 2 (Post -saline)  N xx 
 Mean ¬± SD  xxx.x ¬± xx.x  
 Median  xxx.x  
 Range  xxx.x ‚Äì xxx.x 
Visit 3 (Pre-saline)    
Visit 3 (Post -saline)    
Visit 4 (Pre -saline)    
Visit 4 (Post -saline)    
Visit 5 (Pre -saline)    
Visit 5 (Post -saline)    
   
 
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
clr_17_08-statistical-methods
Page 37

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 37 of 64  
 
T16.1.9.11 Summary of Pre-challenge  Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second  (FEV1) 
(Pharmacodynamic Population) 
T16.1.9.12 Summary of Pre-challenge  Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second  (FEV1) 
(Per-Protocol Population ) 
  
clr_17_08-statistical-methods
Page 38

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 38 of 64 T16.1.9.13 Overall Summary of Adverse Events  
(Safety Population) 
Description  Treatment A  
N = xx 
n (%) Treatment B  
N = xx 
n (%) Treatment C  
N = xx 
n (%) Treatment D  
N = xx 
n (%) Total 
N = xx 
n (%) 
Subjects  in Safety Analysis P opulation  xx xx xx xx xx 
  Subjects  with at least one AE  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
  Discontinued study drug due to above AEs  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
      
AEs reported  xx xx xx xx xx 
  Mild  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
  Moderate  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
  Severe  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
  Not Related  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
  Related  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
  Death  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
  Serious AE  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
      ‚ÄúCertain, Probable and Possible‚Äù  were  assessed as ‚ÄúRelated‚Äù  while  ‚ÄúUnlikely and Unrelated‚Äù  were assessed as ‚ÄúNot Related‚Äù.  
 
 
            
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 39

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 39 of 64 T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_1196] 
(Safety Population) 
Body System / 
MedDRA Term  Treatment A  
N = xx  Treatment B   
N = xx  Treatment C  
N = xx    Treatment D  
N = xx  
Fisher‚Äôs 
P-value Events Subjects 
n (%)  Events Subjects 
n (%) Events Subjects 
n (%) Events Subjects 
n (%) 
Patient w ith at least 
one AE  xx xx (xx.x)   xx xx (xx.x) xx xx (xx.x) xx xx (xx.x) x.xxxx  
Ear and laby[CONTACT_258746] / Ear pain  xx xx (xx.x)   xx xx (xx.x) xx xx (xx.x) xx xx (xx.x) x.xxxx  
      
      
etc.      
      
      
  N= number of subjects  in the safety population  in that particular group ; n= number of subjects  with data availab le for that particular group;   
% is based on N  
 
 Programming Note : Note that if the overall Fisher‚Äôs exact test is significant for comparisons across the 4 treatment s then pair -wise testing between treatments 
will be conducted to determine which contrasts are significant .  
                                    
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
 
  
clr_17_08-statistical-methods
Page 40

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 40 of 64 T16.[IP_ADDRESS] Summary of Frequency of Serious  Adverse Events by [CONTACT_1196] 
(Safety Population) 
Body System / 
MedDRA Term  Treatment A  
N = xx  Treatment B  
N = xx  Treatment C  
N = xx    Treatment D  
N = xx  
Fisher‚Äôs 
P-value Events Subjects 
n (%)  Events Subjects 
n (%) Events Subjects 
n (%) Events Subjects 
n (%) 
Patient w ith at least 
one AE  xx xx (xx.x)   xx xx (xx.x)  xx xx (xx.x)  xx xx (xx.x)  x.xxxx  
Ear and laby[CONTACT_258746] / Ear pain  xx xx (xx.x)   xx xx (xx.x)  xx xx (xx.x)  xx xx (xx.x)  x.xxxx  
      
      
etc.      
      
      
  N= number of subjects in the safety population in that particular group ; n= number of subjects  with data available for that particular group;  
% is based on N  
 
 Programming Note : Note that if the overall Fisher‚Äôs exact test is significant for comparisons across the 4 treatments then pair -wise testing between treatments 
will be conducted to determine which contrasts are significant .  
                                    
 
 
Created on: ddmmmyy hh:mm Page 1 of N   
clr_17_08-statistical-methods
Page 41

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 41 of 64 T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_798114]   
(Safety Population) 
Body System / 
MedDRA Term  Treatment A  
N = xx  Treatment B  
N = xx  Treatment C  
N = xx    Treatment D  
N = xx  
Related 
n (%) Not 
Related 
n (%)  Related 
n (%) Not 
Related 
n (%) Related 
n (%) Not Related 
n (%) Related 
n (%) Not Related 
n (%) 
Patient with at least 
one AE  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
Ear and laby[CONTACT_258746] / Ear pain  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
          
          
          
          
                    N= number of subjects  in the safety population in that particular group ; n= number of subjects  with data available for that particular group;  
                    % is based on N  
                ‚ÄúCertain, Probable and Possible‚Äù  were  assessed as ‚ÄúRelated‚Äù  while  ‚ÄúUnlikely and Unrelated‚Äù  were assessed as ‚ÄúNot Related‚Äù.  
 
 
                              
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 42

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 42 of 64 T16.[IP_ADDRESS] Summary of Frequency of Serious  Adverse Events by [CONTACT_798114]   
(Safety Population) 
Body System / 
MedDRA Term  Treatment A  
N = xx  Treatment B  
N = xx  Treatment C  
N = xx    Treatment D  
N = xx  
Related 
n (%) Not 
Related 
n (%)  Related 
n (%) Not 
Related 
n (%) Related 
n (%) Not Related 
n (%) Related 
n (%) Not Related 
n (%) 
Patient with at least 
one AE  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
Ear and laby[CONTACT_258746] / Ear pain  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  
          
          
          
          
                    N= number of subjects in the safety population in that particular group ; n= number of subjects  with data available for that particular group;  
                    % is based on N  
                ‚ÄúCertain, Probable and Possible‚Äù  were  assessed as ‚ÄúRelated‚Äù  while  ‚ÄúUnlikely and Unrelated‚Äù  were assessed as ‚ÄúNot Related‚Äù.  
 
 
                              
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
    
 
clr_17_08-statistical-methods
Page 43

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 43 of 64 T16.[IP_ADDRESS] Summary of Frequency of All Adverse Events by [CONTACT_86945]  
                       (Safety Population) 
 Treatment A  
N = xx  
 Treatment B  
N = xx  Treatment C  
N = xx  Treatment D  
N = xx 
Body System / 
MedDRA Term  Mild 
n (%) Moderate  
n (%) Severe 
n (%)  Mild 
n (%) Moderate  
n (%) Severe 
n (%) Mild 
n (%) Moderate  
n (%) Severe 
n (%)  Mild 
n (%) Moderate  
n (%) Severe 
n (%) 
Patient with at least 
one AE  xx (xx.x)  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  
Ear and laby[CONTACT_258746] / Ear pain  xx (xx.x)  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  
           
           
           
           
  N= number of subjects  in the saf ety population  in that particular group ; n= number of subjects  with data available for that particular group;  
% is based on N  
 
                                     
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
 
 
  
clr_17_08-statistical-methods
Page 44

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 44 of 64 T16.[IP_ADDRESS] Summary of Frequency of Serious  Adverse Events by [CONTACT_86945]  
                       (Safety Population) 
 Treatment A  
N = xx  
 Treatment B  
N = xx  Treatment C  
N = xx  Treatment D  
N = xx 
Body System / 
MedDRA Term  Mild 
n (%) Moderate  
n (%) Severe 
n (%)  Mild 
n (%) Moderate  
n (%) Severe 
n (%) Mild 
n (%) Moderate  
n (%) Severe 
n (%)  Mild 
n (%) Moderate  
n (%) Severe 
n (%) 
Patient with at least 
one AE  xx (xx.x)  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  
Ear and laby[CONTACT_258746] / Ear pain  xx (xx.x)  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)  xx (xx.x)   xx (xx.x)  xx (xx.x)  xx (xx.x)  
           
           
           
           
  N= number of subjects in the safety population in that particular group ; n= number of subjects  with data available for that particular group;  
% is based on N  
 
                                     
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 45

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 45 of 64 T16.1.9.17 Summary of Vital Signs  
(Safety Population) 
Vital Signs   
Time 
Point Statistic Treatment A  
N = xx Treatment B  
N = xx Treatment C  
N = xx Treatment D  
N = xx 
Systolic Blood Pressure (mmHg)  Pre-Challenge  n Xx xx xx xx 
  Mean ¬± SD  xxx.x ¬± xx.x  xxx.x ¬± xx.x  xxx.x ¬± xx.x  xxx.x ¬± xx.x  
  Median  xxx.x  xxx.x  xxx.x  xxx.x  
  Range  xxx.x ‚Äì xxx.x xxx.x ‚Äì xxx.x xxx.x ‚Äì xxx.x xxx.x ‚Äì xxx.x 
 Post-Challenge       
       
       
       
       
       
       
Diastolic Blood Pressure (mmHg)        
Pulse Rate (beats/min)        
Respi[INVESTIGATOR_26452] (breaths/min)        
Temperature (F)        
       
 
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 46

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page [ADDRESS_1100676] to Follow -up 
 
     
     
     
     
     
     
     
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 47

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 47 of 64 L16.2.2 Listing of Protocol Deviations 
Patient 
Screen 
Number Patient 
Randomization   
Number Sequence  Event Description  
xx-xxxx  
 xx-xxxxx  
 1 
 Outside Visit Window (Visit 3)  
 
    
    
    
    
    
    
    
    
    
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
  
clr_17_08-statistical-methods
Page 48

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 48 of 64 L16.2.3.1 Listing of Subjects Excluded from the Per -Protocol Population  
Patient 
Screen 
Number Patient 
Randomization   
Number Sequence  Exclusion Reason  
xx-xxxx  
 xx-xxxxx  
 1 
 Patient did not meet IE criterion  
    
    
    
    
    
    
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
  
clr_17_08-statistical-methods
Page 49

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 49 of 64 L16.2.3.2 Listing of Subjects Excluded from the Pharmacodynamic Population  
Patient 
Screen 
Number Patient 
Randomization   
Number Sequence  Exclusion Reason  
xx-xxxx  
 xx-xxxxx  
 1 
 Patient did not meet IE criterion  
    
    
    
    
    
    
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
 
  
clr_17_08-statistical-methods
Page 50

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 50 of 64 L16.2.4.1 Listing of Demographic Data  
Patient 
Screen 
Number Patient 
Randomization   
Number Sequence  Age 
(yrs) Gender Ethnicity  Race 
xx-xxxx  
 xx-xxxxx  
 1 
 21 
 Female  
 Not Hispanic or Latino  
 Black or African American  
 
       
       
       
 
       
       
       
       
       
       
       
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 51

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 51 of 64 L16.2.4.2 Listing of Medical History 
Patient  
Screen  
Number Patient 
Randomization   
Number Sequence  System Diagnosis or 
Surgical 
Procedure  Start Date  End Date  Ongoing 
xx-xxxx  xx-xxxxx  
 1 
 xxxxxxxxxxxxxx  
 xxxxxxxxxxx  
 yyyy -mm-dd 
 yyyy -mm-dd 
  
 
xx-xxxx  
 xx-xxxxx  2 xxxxxxxxxxxxxxxx  
 Xxxxxxxxxxxx  
 yyyy -mm-dd 
  Ongoing  
        
        
        
        
        
        
        
        
        
        
        
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 52

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 52 of 64 L16.2.4.3 Listing of Concomitant Medication 
Patient  
Screen 
Number Patient 
Randomization   
Number Sequence  Medication  Dosage Frequency * Route Start/End  
Date Indication  
xx-xxxx  xx-xxxxx  
 1 
 Lisinopril  20 MG  QD PO yyyy -mm-dd / 
yyyy -mm-dd Hypertension  
         
         
         
         
         
         
         
         
         
         
         
 
    Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
*PRN - As needed; QD ‚Äì Daily (once per day); Q4H - Every 4 hours; Q8H - Every 8 hours; Q12H - Every 12 hours; BID - Twice per day; TID - 3 
times per day; QID - 4 times per day; QOD - Every other day; QS - Every week; QM - Every month; Q3M - Every 3 months  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 53

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 53 of 64 L16.2.5 Listing of Dosing  
Patient  
Screen 
Number Patient 
Randomi
zation   
Number Sequence   
Visit Is the 
Patient 
Eligible for 
Dosing? First 
Actuation 
Time Last 
Actuation 
Time Was the Study 
Product 
Primed?  Was the Patient 
Instructed on 
How to Properly 
Dose? Dispenser Observe 
the Study  
Product Was 
Administered?  Was the Patient 
Compliant with the 
Dosing Instruction?  
xx-xxxx  xx-xxxxx  
 1 
 Visit 2  Yes hh:mm  hh:mm  Yes Yes Yes Yes 
   Visit 3  Yes hh:mm  hh:mm  Yes Yes Yes No (Spray mist was 
seen)  
   Visit 4  Yes hh:mm  hh:mm  Yes Yes Yes Yes 
 
 
 
Visit 5  
Yes 
hh:mm  
hh:mm  
Yes 
Yes 
Yes 
Yes 
           
           
           
           
           
           
           
           
 
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
  
clr_17_08-statistical-methods
Page 54

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 54 of 64 L16.2.6.1 Listing of Methacholine Challenge and Pulse Oximetry  
Patient  
Screen 
Number Patient 
Randomi -
zation   
Number Sequence   
 
Visit Methacholine 
Bronchoprovocation 
Challenge  
Administration Time  Time FEV 1 
Reduced  
by ‚â• 20% Treatment 
Dose (mcg)  PC20 
(mg/mL)   Pulse 
Oximetry 
Time Pulse 
Oximetry  
 (%) FEV1 at Time 
of Discharge  
(L)  
xx-xxxx  xx-xxxxx  
 1 
 Visit 1  
hh:mm  hh:mm  NA xxx.x  hh:mm  xx.x xxx.x  
   Visit 2  hh:mm  hh:mm  Placebo, 0  xxx.x  hh:mm  xx.x xxx.x  
 
 
 
Visit 3  
hh:mm  
hh:mm  
Test, 90  
xxx.x  
hh:mm  
xx.x 
xxx.x  
 
 
 
Visit 4  
hh:mm  
hh:mm  
Reference, 90  
xxx.x  
hh:mm  
xx.x 
xxx.x  
 
 
 
Visit 5  
hh:mm  
hh:mm  Reference, 180  xxx.x  hh:mm  xx.x xxx.x  
           
           
           
           
           
           
           
           
 
Note: Methacholine Bronchoprovocation Challenge administration t ime refers to the time of the start of the first MC bronchoprovocation 
challenge administration . 
 
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 55

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 55 of 64 L16.2.6.2 Listing of Methacholine Challenge Stages 
Patient   
Screen 
Number Patient 
Randomi -
zation   
Number Sequence   
Visit StageN Stage FEV1 FVC  
FEV1/FVC x [ADDRESS_1100677]-Saline  
0.0312  
0.0625  
0.1250  
0.2500  
0.5000  
1.0000  
2.0000  
4.0000  
8.0000  
16.0000  x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  x.xxx
 
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
x.xxx  
 x.xxx  
x.xxx  
x.xxx  
x.xxx  xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxx
x 
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
 xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
clr_17_08-statistical-methods
Page 56

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 56 of 64 Visit 2  
Visit 2  
Visit 2  
Visit 2  11 
12 
13 
14 32.0000  
64.0000  
128.0000  
Recovery  x.xxx  
x.xxx  
x.xxx  
x.xxx  x.xxx  
x.xxx  
x.xxx  
x.xxx  xx.xxxx  
xx.xxxx  
xx.xxxx  
xx.xxxx  
         
 
 
 
Visit 3  
 
 
 
 
 
 
 
 
Visit 4  
 
 
 
 
 
 
 
 
Visit 5  
 
 
 
 
 
         
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
                             Visit 3 -5 will be the same as Visit 2.  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 57

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page [ADDRESS_1100678]  
Patient  
Screen 
Number Patient 
Randomization   
Number Sequence  Visit Is the Qualifying FEV 1 >= 80% 
Predicted Value? / and within 88 -
112% of Qualifying FEV 1 from 
the Screening Visit?  Was a 2-Minute Inhalation 
of a Normal Sterile Saline 
Control Administered?  Was the Post-saline FEV 1 
<= a 10% Drop from the 
Qualifying FEV 1 and 
>=70% of Predicted Value?  
xx-xxxx  xx-xxxxx 1 Visit 2  Yes Yes Yes 
   Visit 3  Yes Yes Yes 
   Visit 4  Yes Yes Yes 
   Visit 5  Yes Yes Yes 
       
       
       
       
       
 
       
       
       
       
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
 
  
clr_17_08-statistical-methods
Page 58

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 58 of 64 L16.2.7.1 Listing of Adverse Events (Safety Population Randomization Period) 
 
Treatment  Patient 
Randomi -
zation 
Number System Organ Class  / 
MedDRA Term /  
AE Term Start /End  
 Date Severity Relationship  
to Study 
Drug Outcome  Action 
Taken Other 
Action 
Taken SAE? 
Treatment A  xx-xxxxx  Nervous system disorders /  
Headache /  
Headache  yyyy -mm-dd / 
yyyy -mm-dd Mild  Possible   Recovered  Dose Not 
Changed  None  No 
          
          
Treatment B           
Treatment C           
Treatment D           
 
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 59

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 59 of 64 L16.2.7.2 Listing of Adverse Events  (Safety Population Screening Period ) 
Patient 
Screen 
Number System Organ Class  / 
MedDRA Term /  
AE Term  Start /End  
 Date Severity Relationship  
to Study 
Drug Outcome  Action 
Taken Other 
Action 
Taken SAE? 
xx-xxxx  Nervous system disorders /  
Headache /  
Headache  yyyy -mm-dd / 
yyyy -mm-dd Mild  Possible  Recovered  Dose  Not 
Changed  None  No 
         
         
         
         
         
 
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 60

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page [ADDRESS_1100679] Results  
Patient  
Screen  
Number Patient 
Randomization   
Number Sequence  Visit  Results 
xx-xxxx  xx-xxxxx  1 Visit 3  Positive  
     
     
     
     
     
     
     
     
     
 
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
 
 
  
clr_17_08-statistical-methods
Page 61

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 61 of 64 L16.2.7.4 Listing of Abnormal Physical Examinations 
Patient  
Screen  
Number Patient 
Randomization   
Number Sequence  Visit  Body 
System  
Result 
xx-xxxx  xx-xxxxx  1 Visit 1  xxxxxxx  Abnormal (xxxxx)  
      
      
      
      
      
      
      
      
      
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
 
Created on: ddmmmyy hh:mm  Page 1 of N 
 
  
clr_17_08-statistical-methods
Page 62

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 62 of 64 L16.2.8.1 Listing of Vital Signs  
Patient  
Screen 
Number Patient 
Randomization   
Number Sequence  Visit Time Point  Systolic BP  
(mmHg) Diastolic BP  
(mmHg) Pulse Rate 
(beats/min)  Respi[INVESTIGATOR_634794] 
(breaths/min)  Temperature  
(F) 
xx-xxxx  xx-xxxxx  [ADDRESS_1100680]-Challenge  140 80 74 18 97.0 
          
          
          
 
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 63

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 63 of 64 L16.2.8.2 Listing of 12-Lead ECG  
Patient  
Screen 
Number Patient 
Randomization   
Number Sequence  Visit ECG 
Date ECG 
Time ECG  
Result Comments  
xx-xxxx  xx-xxxxx  1 Visit 1  yyyy -mm-dd hh:mm  Abnormal (Not Clinically 
Significant)  xxxxxxxxxxxxxxxxxxxx  
        
        
        
        
        
        
        
        
 
        
        
        
        
Sequence: 1=ABCD, 2=DCBA, 3=CADB, 4=BDAC  
 
 
Created on: ddmmmyy hh:mm  Page 1 of N  
  
clr_17_08-statistical-methods
Page 64

 
STATISTICAL ANALYSIS PLAN  
 
Albuterol Sulfate Inhalation Aerosol                                                                         Protocol / Study No.  AI CLR_17_08 /  
 
12/21/2018                                              ÔÇ° Sun Pharmaceuticals Industries Limited  ÔÇ°                                                         Page 64 of 64 REFERENCES  
 
1. American Thoracic Society - Guidelines for Methacholine and Exercise Challenge Testing. American journal of respi[INVESTIGATOR_116880] 161, 309 -329 (1999). 
2. Saluja B, D. R., Kim SH, Lee SL. in Respi[INVESTIGATOR_798097].  413-416. 
3. Draft Guidance on Orlistat.   Food and Drug Administration's Office of Generic Drugs. Recommended Feb 2010, Revised Aug 
2010. Retrieved on Jan 15 2018 from: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201268.pdf 
4. Draft Guidance on Albuterol Sulfate.  Food and Drug Administration's Office of Generic Drugs. Recommended Apr 2013, 
Revised Dec  2016. Retrieved on Jan 15 2018 from: 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM346985.pdf  
5. Inman MD, Hamilton AL, Kerstjens HAM, Watson RM, O‚ÄôBy[CONTACT_21143]. The utility of methacholine airway responsiveness 
measurements in evaluating anti-asthma drugs . J Allergy Clin Immunol.  1998;101(3):342-348 
6. Mauger EA, Mauger DT, Fish JE, Chinchili VM, Israel E. Summarizing Methacholine Challenges in Clinical Research . Control 
Clin Trials. 2001;22([ADDRESS_1100681]):244S-251S 
7. Efron B, Tibshirani RJ.  An Introduction to the Bootstrap.  (Chapman & Hall: [LOCATION_001], NY, 1993) 
8. Gibaldi M, Perrier D. Pharmacokinetics , Second Edition, R evised  and Expanded. (Marcel Dekker Inc: [LOCATION_001], NY, 1982) 
9. Bonate PL.   Pharmacokinetic-Pharmacodynamic Modeling and Simulation, Second Edition.  (Springer Science+Business Media, 
Inc: [LOCATION_001], NY, 20 11) 
10. StatLib, Department of Statistics, Carnegie Mellon University (http://lib.stat.cmu.edu ) 
 
clr_17_08-statistical-methods
Page 65

1 
 
 
 
NOTE TO FILE  
 
 
STUDY TITLE: A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-
Period, Four-Sequence, Four-Treatment, Placebo and Active Controlled, Comparative, 
Multiple-Center, Crossover-Design, Bronchoprovocation Study to Evaluate the 
Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg base 
(Sun Pharmaceuticals Industries Limited) to PROAIR¬Æ HFA (albuterol sulfate) 
Inhalation Aerosol, eq 90 mcg base (Teva Respi[INVESTIGATOR_696], LLC) in Subjects With Stable, 
Mild Asthma 
PROTOCOL NO.:  CLR_17_08  (Revision 6 .0) 
  
 
This Note to File explains the changing of numbering as per ICH guidance E3 for Tables, 
Listings and Figures that are i
ncluded in the final SAP dated December 21, 2018.  
 
 
T14.1.1 Summary of Patie
nt Disposition
 
T14.1.2 Summary of Protocol Deviations
 
T14.1.3 Summary of Patient‚Äôs Treatments Included in the Pharmacodynamic Analysis
  
T14.1.4 Summary of Demographic Data and Baseline Characteristics
 
T14.1.5 Summary of Demographic Data and Baseline Characteristics
 
T14.1.6 Summary of Demographic Data and Baseline Characteristics
 
T14.2.1.1 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV 1 by 20% (PC 20)  (Safety Population)  
T14.2.1.2 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV 1 by 20% (PC 20)  (Pharmacodynamic Population) 
T14.2.1.3 Summary of Concentration (mg/mL) of Methacholine Required to Reduce 
FEV 1 by 20% (PC 20)   (Per-Protocol Population) 
T14.2.2.1 Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second 
(FEV 1)
 (Safety Population) 
 T14.2.2.2 Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second 
(FEV 1)
 (Pharmacodynamic Population) 
T
[IP_ADDRESS] Summary of Pre-challenge Forced Expi[INVESTIGATOR_117067] (flow rate) in 1 second 
(FEV 1)
 (Per-Protocol Population) 
T14.3.1.1 Overall Summary of Adverse Events
 
T14.3.1.2 Summary of Frequency of All Adverse Events by [CONTACT_1196]
 
T14.3.1.3 Summary of Frequency of Serious Adverse Events by [CONTACT_1196]
 
T14.3.1.4 Summary of Frequency of All Adverse Events by [CONTACT_80184]
 
T14.3.1.5 Summary of Frequency of Serious Adverse Events by [CONTACT_456827]
 
T14.3.1.6 Summary of Frequency of All Adverse Events by [CONTACT_798115]_17_08-statistical-methods
Page 66

clr_17_08-statistical-methods
Page 67
